H.C. Wainwright reiterated its Buy rating on Wave Life Sciences and maintained its $13.00 price target on October 2, 2026. The action followed the company’s announcement the previous day that it had aligned with the U.S. Food and Drug Administration (FDA) on the registrational pathway for WVE-006, a treatment for alpha-1 antitrypsin deficiency (AATD).
The FDA agreed to a single two-year registrational trial, with potential for accelerated approval after a one-year interim analysis. H.C. Wainwright described the pathway as capital-efficient and said it validated Wave’s prior data and analyses for its investigational RNA editing treatment.